Actavis Tells Judge Purdue's Oxy Patents Rely On Minor Tweak

Law360, New York (November 16, 2012, 5:38 PM EST) -- A chemical tweak should not allow Purdue Pharma LP to monopolize sales of the popular pain killer oxycodone for years, Actavis Elizabeth LLC argued Friday in a trial over whether Purdue's oxycodone patents should be killed.

New oxycodone patents from Stamford, Conn.-based Purdue subtly shift their explanation of the chemistry behind the best-selling painkiller, but in practical terms do not add anything to what was already known, lawyers for Actavis said at the opening of a trial before U.S. District Judge Sidney Stein in Manhattan....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.